This study evaluates the effectiveness of the WID-qCIN test, an innovative DNA methylation-based triage method, in a real-world population of women aged 30 years and older who underwent cervical cancer screening in Stockholm between January and March 2017. The WID-qCIN test assesses DNA methylation in three human genes (*DPP6*, *RALYL*, and *GSX1*) and is combined with HPV16 and/or HPV18 genotyping. The analysis included 2,377 HPV-positive samples, and the combination of WID-qCIN (with a predefined threshold) and HPV16/18 detected 93.4% of cervical intraepithelial neoplasia grade 3 (CIN3) and 100% of invasive cervical cancers (CCs). The WID-qCIN/HPV16/18 combination predicted 69.4% of incident CIN2 or worse cases, compared to 18.2% predicted by cytology. The study found that cytology or WID-qCIN/HPV16/18 triage would require 4.1 and 2.4 colposcopy referrals, respectively, to detect one CIN2 or worse case over a 6-year period. These findings support the use of WID-qCIN/HPV16/18 as an improved triage strategy for HPV-positive women, offering a more sensitive and specific approach compared to cytology.This study evaluates the effectiveness of the WID-qCIN test, an innovative DNA methylation-based triage method, in a real-world population of women aged 30 years and older who underwent cervical cancer screening in Stockholm between January and March 2017. The WID-qCIN test assesses DNA methylation in three human genes (*DPP6*, *RALYL*, and *GSX1*) and is combined with HPV16 and/or HPV18 genotyping. The analysis included 2,377 HPV-positive samples, and the combination of WID-qCIN (with a predefined threshold) and HPV16/18 detected 93.4% of cervical intraepithelial neoplasia grade 3 (CIN3) and 100% of invasive cervical cancers (CCs). The WID-qCIN/HPV16/18 combination predicted 69.4% of incident CIN2 or worse cases, compared to 18.2% predicted by cytology. The study found that cytology or WID-qCIN/HPV16/18 triage would require 4.1 and 2.4 colposcopy referrals, respectively, to detect one CIN2 or worse case over a 6-year period. These findings support the use of WID-qCIN/HPV16/18 as an improved triage strategy for HPV-positive women, offering a more sensitive and specific approach compared to cytology.